Mobile Motivational Physical Activity Targeted Intervention
CompletedNAResults postedLast updated 25 April 2023
What this trial tests
NA trial testing Motivaltional interviews and infrequent motivational text messages in Osteoarthritis in 24 participants. Completed in 30 September 2018.
Timeline
1 June 2017
Primary endpoint 31 August 2018
30 September 2018
Quick facts
Lead sponsor
University of Washington
Phase
NA
Status
Completed
Study type
INTERVENTIONAL
Allocation
na
Design
single group
Masking
none
Primary purpose
treatment
Enrollment
24
Start date
1 June 2017
Primary completion
31 August 2018
Estimated completion
30 September 2018
Sites
1 location across United States
Drugs / interventions tested
Motivaltional interviews and infrequent motivational text messages
65 and older, any sex, with Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Mixed Effect Model Inferential Estimates of Longitudinal Changes Across 3 Time Points (Baseline, Week 14, Week 19) in Insomnia Severity IndexPrimary· Assessed at Baseline, week 14, week 19; change from baseline throughout three time points reported
Insomnia Severity Index (ISS)
Score range 0 to 28 at each time point, with higher scores indicating more severe insomnia symptoms
A single value for change in ISS across three-time points was calculated using linear mixed effect modeling
Group
Value
95% CI
Motivational Interview and Text Messages
-1.24
-2.43 – -0.05
Mixed Effect Model Inferential Estimates of Longitudinal Changes Across Three Time Points (Baseline, Week 14, Week 19) in Actigraphy Total Sleep Time (TST)Primary· Assessed at Baseline, week 14, week 19; change from baseline throughout three time points reported
Actigraphy Total Sleep Time (TST) in minutes was calculated using baseline, week 14, and week 19 data from a wrist-worn actigraph
A single value for change in TST across three-time points was calculated using linear mixed effect modeling
A negative change score indicates lower TST ( in min) over time
Group
Value
95% CI
Motivational Interview and Text Messages
-4.5
-13.4 – 4.4
Mixed Effect Model Inferential Estimates of Longitudinal Changes Across Three Time-points (Baseline, Week 14, Week 19) in Self-Efficacy (SE) to Manage Chronic Disease ScaleSecondary· Assessed at Baseline, week 14, week 19; change from baseline throughout three time points reported
Self-Efficacy to Manage Chronic Disease Scale
Score range 1 to 10, with higher scores indicating better efficacy.
A single value for change in SE across three-time points was calculated using linear mixed effect modeling
Positive change score indicates an improvement in self-efficacy over time
Group
Value
95% CI
Motivational Interview and Text Messages
0.28
-0.07 – 0.63
Mixed Effect Model Inferential Estimates of Longitudinal Changes Across Three Time-points (Baseline, Week 14, Week 19) in Pain ScoreSecondary· Assessed at Baseline, week 14, week 19; change from baseline throughout three time points reported
Pain
Score range 1 to 10, with higher scores indicating worse symptoms.
A single value for change in pain across three-time points was calculated using linear mixed effect modeling
Positive change score indicates worsening in pain over time
Group
Value
95% CI
Motivational Interview and Text Messages
-0.13
-0.47 – 0.20
Mixed Effect Model Inferential Estimates of Longitudinal Changes Across Three Time-points (Baseline, Week 14, Week 19) in Objectively Measured Step CountSecondary· Assessed at Baseline, week 14, week 19; change from baseline throughout three time points reported
Fitbit devices were used to measure weekly step count at baseline, and week 14, and week 19
A single value for change in step count across three-time points was calculated using linear mixed effect modeling
A positive change indicates increased step count over time
Group
Value
95% CI
Motivational Interview and Text Messages
45.6
-311.6 – 402.9
Sponsor's own description
More than 50% of older persons with osteoarthritis (OA) experience disrupted sleep and insomnia symptoms of difficulty falling asleep, awakening during the night, and awakening too early and being unable to fall back to sleep. Because OA pain has been implicated in sleep problems and because physical exercise interventions have been found to improve pain and sleep quality, staying physically active during the daytime is likely advantageous in terms of improving sleep. Physical exercise interventions with a duration between 10 and 16 weeks have been shown to improve quality of sleep in older adults with self-reported disrupted sleep. Unfortunately, recent reports show that older adults with OA are mainly sedentary and few meet national guidelines for recommended amounts of daily physical activity. A self-management intervention that integrates use of mobile technology to prompt older adults to be physically active, provides ongoing monitoring of the amount of their physical activity and includes self-efficacy enhancements is a novel non-pharmacological intervention both for prevention and treatment of sleep deficiency in persons with OA.
The proposed study will involve delivery of automatic physical activity-focused text messages, a novel sleep self-management diary (SleepTight) and motivational interviewing in participants with OA of the hip or knee (most commonly affected joints). The purpose of this Project is to pilot test a new self-management program: MobMPATI, a multidimensional, tailored intervention for sleep deficiency in for older adults with OA. The specific aims are to:
1. Test the acceptability of MobMPATI for older adults with OA and poor sleep quality as a manifestation of sleep deficiency.
2. Test the feasibility of implementing MobMPATI for older adults with OA, as well as collecting electronic data from the sample.
3. Explore pre/posttest changes in self-efficacy, motivation and sleep deficiency measures \[total sleep time (TST) and sleep efficiency (SE)\] with the MobMPATI intervention.
This study will provide feasibility/acceptability and preliminary data necessary for a larger clinical trial of MobMPATI intervention to encourage physical activity and reduce sedentary behavior in older adults with OA as a way of reducing sleep deficiency. Preliminary testing of the intervention will indicate what measures are more sensitive in promoting self-efficacy and motivation so that a smaller number of outcomes could be monitored to reduce participant burden. This study is the first step in this innovative program of research. The knowledge gained will provide data on the benefit of a potentially cost-effective intervention that could be implemented on a large scale to improve health of older adults with OA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07404891 — Clinical Trial on the Efficacy and Safety of ALT001 in Osteoarthritis
· NA
· recruiting
NCT07118501 — A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System
· recruiting
NCT06631638 — EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
· NA
· recruiting
NCT07198750 — "Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis"
· NA
· recruiting
NCT07006714 — Preoperative Correction of Vitamin D Deficiency in Total Joint Arthroplasty (TJA)
· Phase 4
· active not recruiting
Other University of Washington trials
Trials by the same sponsor.
NCT07430852 — Inherited and Environmental Risks Acting on Body Weight
· NA
· not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc
· Phase 2
· not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn
· NA
· not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle
· Phase 2
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 25 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03160287.